Boston Partners boosted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.3% during the second quarter, Holdings Channel reports. The institutional investor owned 1,277,442 shares of the medical equipment provider’s stock after buying an additional 40,826 shares during the period. Boston Partners’ holdings in Zimmer Biomet Holdings were worth $164,024,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZBH. BlackRock Inc. increased its stake in Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after buying an additional 16,336,262 shares in the last quarter. Harbour Capital Advisors LLC increased its stake in Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock worth $10,145,000 after buying an additional 1,292,773 shares in the last quarter. Nordea Investment Management AB increased its stake in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares in the last quarter. Glenview Capital Management LLC purchased a new stake in Zimmer Biomet Holdings during the first quarter worth approximately $94,197,000. Finally, Point72 Asset Management L.P. increased its stake in Zimmer Biomet Holdings by 230.3% in the first quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock worth $128,643,000 after buying an additional 734,500 shares in the last quarter. Institutional investors own 83.62% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 111.70 on Friday. The company has a market cap of $22.59 billion, a PE ratio of 31.81 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49. The company has a 50-day moving average price of $124.93 and a 200 day moving average price of $121.26.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.10 by $0.02. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.02 EPS. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is 27.59%.

COPYRIGHT VIOLATION WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by Boston Partners” was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/08/12/zimmer-biomet-holdings-inc-zbh-shares-bought-by-boston-partners.html.

A number of brokerages have issued reports on ZBH. Needham & Company LLC upped their price objective on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price objective on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Friday, April 28th. Goldman Sachs Group, Inc. (The) began coverage on Zimmer Biomet Holdings in a research report on Tuesday, May 16th. They set a “sell” rating and a $92.00 price objective on the stock. Wells Fargo & Company downgraded Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research report on Friday, April 28th. Finally, Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $136.90.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.